Complete Genomics, Inc. (GNOM) Posts Q3 Loss of $0.65, Offers Q4 Volume Outlook
Tweet
Share
E-mailGet Alerts GNOM Hot Sheet
Join SI Premium – FREE
Complete Genomics, Inc. (NASDAQ: GNOM) reported Q3 EPS of ($0.65), $0.11 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $3.73 million.
The company shipped approximately 2,400 genomes to its customers in the three quarters of 2011. In the fourth quarter, the company expects to ship between 900 and 1,200 genomes, bringing the total shipments for the year to between 3,200 and 3,600. This range reflects uncertainty in the cycle time for genomes that are currently in process
The company shipped approximately 2,400 genomes to its customers in the three quarters of 2011. In the fourth quarter, the company expects to ship between 900 and 1,200 genomes, bringing the total shipments for the year to between 3,200 and 3,600. This range reflects uncertainty in the cycle time for genomes that are currently in process
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Star Equity Holdings (STRR) Misses Q2 EPS by 8c
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
